S 694 · in committee · significant
PLASMA Act
- healthcare
What this bill does
- This bill gradually reduces Medicare drug discounts for plasma-derived products over several years instead of applying full discounts immediately.
- Medicare beneficiaries who use plasma-derived medications are affected, as are the manufacturers of these products.
- Discounts phase in from 1% in 2026 to full rates (10-20%) by 2030-2032 under the Medicare drug benefit program.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How might a gradual phase-in of Medicare drug discounts for plasma products affect patients who depend on these medications during the transition years?
- 02
What evidence supports the claim that delaying full discounts will encourage plasma manufacturers to invest in research and development?
- 03
Which groups would benefit financially from slower implementation of these discounts, and what trade-offs might occur for Medicare's budget?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · R-NC
Thom Tillis
Citizen cosponsors
0
In Congress
3/ 100
Senators cosponsoring
Introduced 2025-02-24
Joining the bill
Legislative timeline
2025-02-24 · senate · IntroReferral
Read twice and referred to the Committee on Finance.
2025-02-24 · IntroReferral
Introduced in Senate
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.